Navigation Links
Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Date:11/18/2010

NEW YORK, Nov. 18, 2010 /PRNewswire/ -- The final hearing for approval of the class settlement in the long-running class action gender discrimination case brought by female sales representatives at Novartis Pharmaceutical Corporation is set for Friday, November 19th at 10 a.m. in the courtroom of Judge Colleen McMahon of United States District Court for the Southern District of New York in Manhattan.

The plaintiffs are seeking Court approval for the unopposed final settlement agreement. The settlement terms include the disbursement of $175 million – $152.5M of which includes 100% of back pay, benefits and adjusted wages, compensatory damages, service payments to class representatives and class members who helped prosecute the case, attorneys' fees and case expenses. In addition to the monetary relief, the settlement includes $22.5M of non-monetary relief which Novartis will invest, as required by the terms of the settlement, to engage in substantive programmatic changes to improve employment practices at Novartis. This is believed to be one of the largest non-monetary settlements ever reached.

The plaintiffs are also requesting that the Court approve a final certification of the settlement class, which currently totals some 6,026 women who worked for the pharmaceutical giant during the class period that now extends from July 15, 2002 through July 14, 2010.

"This is an excellent monetary agreement for female sales representatives of Novartis," said Mr. Sanford. "More important, Novartis will be a better company going forward; it is changing its ways and is doing the right thing."

The class is represented by a team of attorneys from Sanford Wittels & Heisler LLP (SWH), a boutique class-action civil rights litigation law firm with offices in New York, Washington, D.C., and San Francisco. The Novartis litigation team is headed by SWH partners

SOURCE Sanford Wittels & Heisler LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 North American lighting leader OSRAM SYLVANIA ... for the new OSRAM ITOS ® PHASER ® ... for microscopy, endoscopy and surgical head lamps that delivers the ... and lamp life. "We,re honored to be recognized ... innovative new technologies of the past year," said Andreas ...
(Date:8/27/2014)... 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... pharmaceutical development, clinical trial manufacturing, and advanced analytical and ... it will participate at the upcoming Rodman & Renshaw ... held in New York . The ... September 9, 2014 at the New York Palace Hotel. ...
(Date:8/27/2014)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the same ... the quarter of $240,156 compared to net income of $238,826 ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... March 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company update at the Barclays ... at 4:15 p.m. ET.   Interested parties may ... the investor section of the BioMarin website, www.BMRN.com . ...
... (Nasdaq: VRML ) –Vermillion, a molecular ... data from its collaboration with Johns Hopkins University School ... specificity of CA125 for the identification of malignant ovarian ... Meeting on Women,s Cancer of the Society of Gynecologic ...
Cached Medicine Technology:BioMarin to Present at the Barclays Global Healthcare Conference 2Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test 2Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test 3
(Date:8/27/2014)... The American College of ... management and treatment of pulmonary arterial hypertension (PAH) ... in Adults: CHEST Guideline, in the journal CHEST. ... and provide the latest and most accurate treatment ... Association (PHA) – the country’s leading pulmonary ...
(Date:8/27/2014)... HealthDay Reporter WEDNESDAY, Aug. 27, 2014 (HealthDay ... alley will likely never want to return there, having associated ... neuroscientists working with mice say they,ve discovered the brain circuit ... emotions. And in rodent tests, they,ve manipulated brain cells to ... they made once-reluctant mice want to return to that dark ...
(Date:8/27/2014)... MI (PRWEB) August 27, 2014 Michigan Head ... help the children of a local elementary school by ensuring ... Siersma Elementary School has year-round attendance, and Michigan Head & ... to meet the new school year. , "There are a ... this is a great way to give back to our ...
(Date:8/27/2014)... The federal judge overseeing thousands of ... the deadline for plaintiffs to enroll in the U.S. ... by U.S. District Judge David Katz of the Northern ... DePuy ASR Settlement Program must do so by September ... Implant Products Liability Litigation – MDL 2197) , “Our ...
(Date:8/27/2014)... News) -- Pouring half a glass of wine at a time ... study. Researchers asked 74 college students and staff to pour ... had varying amounts of wine in them. The participants were told ... a "rule of thumb" about how much to pour -- such ... the top -- poured less wine than those without set guidelines. ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
... Center,s Average ER Wait TimePANAMA CITY, Fla., May 21 ... area to find out the average ER wait time at ... The hospital is posting its average ER wait times ... became the only hospital in our area to post our ...
... opened door to NUHW organizing effortOAKLAND, Calif., May 21 ... the recent decision by the California Public Employee Relations ... Medical Center (DMC) in San Pablo to continue. The ... violations of labor law by DMC management and organizers ...
... span in mice may hold hope for people, , , THURSDAY, ... discovered a way to boost chemotherapy and slightly extend the ... for more effective treatments in people. , There,s no guarantee ... it did, the researchers don,t expect that it would add ...
... and Financing Offerings Help Healthcare Providers to Accelerate ... May 21 Perot Systems Corporation (NYSE: ... today announced the availability of financing options to ... implementation of electronic health records which are being ...
... Committee, the region,s most prominent business organization, today applauded ... Board report in Atlanta, Georgia. Greater Baltimore Committee ... Board process has been of great value to the ... is appreciated by the business community. He is ...
... health and economic data like you,ve never seen it ... Hans Rosling will show how reproductive health ... will also illustrate how the convergence of conditions around ... "Western" and "developing" categories an outdated concept.On Tuesday, ...
Cached Medicine News:Health News:ER Wait Times at Your Fingertips 2Health News:Doctors Medical Center Election Tainted 2Health News:A New Way to Get Chemo to Pancreatic Tumors 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 2Health News:Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades 3Health News:Gapminder's Hans Rosling Brings Poverty, Health Data to Life at Wilson Center 2
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
Periosteal elevator #9H, 17.5 cm, 7"....
Medicine Products: